BA3071

BA3071 is a monoclonal antibody developed by BioAtla. Its target is CTLA-4 (the sponsor names CTLA-4). The sponsor states: A Conditionally Active Biologic (CAB-C) anti-CTLA-4 antibody engineered to bind and block CTLA-4 preferentially within the tumour microenvironment (rather than systemically), activating T cells locally to reduce systemic toxicity. ClinicalTrials.gov describes the intervention as: Conditionally active biologic (CAB) antibody that binds to CTLA-4. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer and melanoma. The largest, NCT05180799, plans to enrol 320 participants with primary completion expected 2025-03-19. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.